Micro-cap biotech Aeglea BioTherapeutics has impressed investors with a rapid pivot into the field of autoimmune disease, with the acquisition of Spyre Therapeutics.
Rare disease drug developer Aeglea has been in danger of going bust after its lead candidate, pegtarviliase, a treatment for classical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?